Renata to merge with subsidiary
Renata Limited, a listed pharmaceutical company, is going to merge with its subsidiary Renata Oncology Limited subject to approval from the creditors, shareholders and sanction of the High Court Division of the Supreme Court and other legal/regulatory authorities.
The board of directors of the drug maker approved the draft scheme of the amalgamation, with the exchange of 0.02 shares of Renata Limited for each share of Renata Oncology based on net asset value per share as on June 30, 2019.
Comments